QUICK ANSWER · AEO / GEO
A nucleoside analogue and AMPK-related research compound, not a peptide; clinical and anti-doping contexts must be separated.
ENTITY FACTS
What should readers identify first?
What remains unknown?
- long-term safety outside short perioperative research settings
- human risk-benefit for weight, metabolic or performance claims
- effects of repeated exposure on purine, glucose and lipid metabolism
- comparability of research-grade AICAR, acadesine formulations and online products
- current product-specific marketing-authorisation status in Thailand, the EU and UK
- current US compounding-list status under a substance-specific FDA review
What limits these conclusions?
- Strong controlled human evidence exists only in a narrow CABG setting and culminated in a negative confirmatory trial. Older meta-analytic and post-hoc signals must be interpreted in light of RED-CABG. Popular performance claims are based mainly on mouse work. Mechanistic studies also show that AICAR is not selective for AMPK, limiting simple pathway-based conclusions.
This overview does not replace the detailed adverse-event and product-specific risk discussion in the complete Thai profile or the original sources.
EVIDENCE BOUNDARY
What this overview does not establish
- An evidence grade does not rank this molecule against another treatment.
- A molecule name does not establish the identity, purity or regulatory status of a product.
- Animal, cell or biomarker findings do not automatically establish human clinical benefit.
- Approval in one country or indication does not transfer globally.
Where can I check the evidence?
Original sources from the same evidence record used by Compare. Read each source's population, methods, limitations and date; a citation is not product endorsement.
- https://precision.fda.gov/uniisearch/srs/unii/53ief47846
- https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=203105
- https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=341011
- https://www.fda.gov/media/94155/download
- https://www.fda.gov/media/94164/download
- https://clinicaltrials.gov/study/NCT00872001
- https://pubmed.ncbi.nlm.nih.gov/7818622/
- https://pubmed.ncbi.nlm.nih.gov/7574044/
- https://pubmed.ncbi.nlm.nih.gov/9002496/
- https://pubmed.ncbi.nlm.nih.gov/22782417/
- https://pubmed.ncbi.nlm.nih.gov/7744080/
- https://pubmed.ncbi.nlm.nih.gov/18674809/
- https://pubmed.ncbi.nlm.nih.gov/27103440/
- https://pubmed.ncbi.nlm.nih.gov/34064363/
- https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
- https://products.mhra.gov.uk/
- https://www.ema.europa.eu/en/medicines/download-medicine-data
- https://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/FRM_SEARCH_DRUG.aspx
FAQ · ANSWER ENGINE
Frequently asked questions
What is AICAR (Acadesine)?
AICAR (Acadesine) is described pharmacologically as Investigational purine nucleoside analogue / adenosine-regulating agent; not a peptide. A nucleoside analogue and AMPK-related research compound, not a peptide; clinical and anti-doping contexts must be separated.
Does AICAR (Acadesine) have strong evidence?
PrimeCoreBio records Evidence Grade B. This grade describes evidence strength, not comparative effectiveness or suitability for an individual.
Is AICAR (Acadesine) approved everywhere?
No global conclusion should be inferred. PrimeCore Class B must be read with the exact product, country and indication on the source-rich profile.
Educational information only. This page does not provide diagnosis, treatment, prescribing, dosage, injection instructions or individual medical advice.